lp-a.org

RNA therapeuticsLandmark

Lp(a)HORIZON: pelacarsen lowers Lp(a) by 78 percent but does not reduce cardiovascular events, hazard ratio 1.02 (Cho et al., NEJM 2026)

Original title: Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a)

N Engl J Med · · 10

Cho L, Nicholls SJ, Frndak S, Wolski K, Nordestgaard BG, Manning B, Leitersdorf E, Landmesser U, Menon V, McCluskey J, Blaha MJ, Morishita R et al.

The first cardiovascular outcomes trial of a targeted Lp(a)-lowering therapy, and a neutral one. 8,350 patients with pre-existing cardiovascular disease and Lp(a) of at least 70 mg per deciliter were randomised to monthly subcutaneous pelacarsen 80 mg or placebo (8,322 in the efficacy analysis; mean age 59.7 years, 27.0 percent women, median Lp(a) 236 nmol per liter). At 12 months Lp(a) was 64.4 versus 233.4 nmol per liter. Over a median 4.7 years the primary endpoint (cardiovascular death, non-fatal MI, non-fatal stroke or urgent coronary revascularisation) occurred in 511 (12.3 percent) versus 503 (12.1 percent) patients, hazard ratio 1.02 (95 percent CI 0.90 to 1.15, P=0.76), and in 12.3 versus 12.3 percent of those with Lp(a) of at least 90 mg per deciliter (hazard ratio 1.00). Serious adverse events 37.3 versus 41.1 percent. Presented at AHA 2026 on 7 November; extended analyses in NEJM Evidence.

Read the paper (DOI)PubMed

Original abstract

Background: Pelacarsen, an antisense oligonucleotide, reduces serum levels of lipoprotein(a). However, the effect of pelacarsen on cardiovascular outcomes remains uncertain.

Methods: We conducted an international, randomized, placebo-controlled trial involving patients with preexisting cardiovascular disease and a lipoprotein(a) level of at least 70 mg per deciliter. Patients were randomly assigned in a 1:1 ratio to receive subcutaneous pelacarsen (80 mg) administered monthly or matching placebo. The primary end point was a major adverse cardiovascular event, defined as a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or urgent coronary revascularization.

Results: A total of 8350 patients underwent randomization, with 8322 included in the efficacy analysis; 4157 patients were assigned to receive pelacarsen, and 4165 to receive placebo. The mean age of the patients was 59.7 years, and 27.0% were women. The median lipoprotein(a) level at baseline was 236 nmol per liter. At 12 months, the lipoprotein(a) level was 64.4 nmol per liter in the pelacarsen group and 233.4 nmol per liter in the placebo group. The median follow-up was 4.7 years. A primary end-point event occurred in 511 patients (12.3%) in the pelacarsen group and in 503 (12.1%) in the placebo group (hazard ratio, 1.02, 95% confidence interval [CI], 0.90 to 1.15, P = 0.76). Among patients with a baseline lipoprotein(a) level of at least 90 mg per deciliter, a primary end-point event occurred in 402 of 3266 patients (12.3%) in the pelacarsen group and in 403 of 3274 (12.3%) in the placebo group (hazard ratio, 1.00; 95% CI, 0.87 to 1.15; P = 0.99). Serious adverse events occurred in 1553 of 4166 patients (37.3%) who received pelacarsen and in 1709 of 4154 (41.1%) who received placebo.

Conclusions: Pelacarsen did not result in a lower risk of major adverse cardiovascular events than placebo at a median follow-up of 4.7 years. (Funded by Novartis; Lp[a]HORIZON ClinicalTrials.gov number, NCT04023552.)See also in NEJM Evidence: Extended Analyses of Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a).

aha 2026epidemiologyoutcomes trialpelacarsenphase 3RNA therapeuticssecondary preventionstroke

Summary written by lp-a.org from the published abstract; figures as published. Page updated 10 November 2026. Methods.